Supernus Pharmaceuticals (SUPN) Accounts Payables (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Accounts Payables of $108.5 million for Q2 2026, up 39.52% year-over-year from $77.7 million in Q2 2025, and up 7.13% on a QoQ basis from $101.2 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Accounts Payables (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Accounts Payables for 16 years, with the latest figure at $108.5 million in Q2 2026.
- Accounts Payables for Q2 2026 came in at $108.5 million, up 39.52% year-over-year; the trailing twelve-month figure through Jun 2026 was $108.5 million (up 39.52% YoY), and the FY2025 annual result was $107.8 million, up 41.19% from the prior year.
- Accounts Payables grew to $108.5 million in Q2 2026, from $101.2 million in the prior quarter.
- Over five years, Accounts Payables peaked at $133.0 million in Q2 2022 and troughed at $75.8 million in Q3 2024.
- A 5-year average of $92.6 million and a median of $87.9 million in 2022 frame the typical range for Accounts Payables.
- The widest annual swing landed in 2022, when Accounts Payables jumped 66.26%; it then plunged 37.56% in 2023.
- A 5-year view of Accounts Payables shows it stood at $96.3 million in 2022, then retreated by 17.41% to $79.6 million in 2023, then retreated by 4.04% to $76.4 million in 2024, then jumped by 41.19% to $107.8 million in 2025, then rose by 0.61% to $108.5 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $108.5 million in Q2 2026, $101.2 million in Q1 2026, and $107.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 356.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn | 108.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.46 Mn |
| Mar 31, 2026 | 101.24 Mn |
| Dec 31, 2025 | 107.80 Mn |
| Sep 30, 2025 | 108.61 Mn |
| Jun 30, 2025 | 77.74 Mn |
| Mar 31, 2025 | 76.89 Mn |
| Dec 31, 2024 | 76.35 Mn |
| Sep 30, 2024 | 75.80 Mn |
| Jun 30, 2024 | 82.61 Mn |
| Mar 31, 2024 | 86.40 Mn |
| Dec 31, 2023 | 79.57 Mn |
| Sep 30, 2023 | 78.47 Mn |
| Jun 30, 2023 | 83.04 Mn |
| Mar 31, 2023 | 95.35 Mn |
| Dec 31, 2022 | 96.34 Mn |
| Sep 30, 2022 | 110.30 Mn |
| Jun 30, 2022 | 133.00 Mn |
| Mar 31, 2022 | 89.43 Mn |
| Dec 31, 2021 | 117.68 Mn |
| Sep 30, 2021 | 72.29 Mn |